Overview:

Malarial parasites are developing resistance to anti-malarial drugs, therefore conventional treatment for malaria has proven to be less efficacious. Malaria vaccines would curb the growth of malarial cases and help save millions. Development of malaria vaccine has been one of the greatest challenges faced by research institutes and manufacturers. Several vaccines have been studied over the years and have failed owing to the nature of plasmodium strain. Therefore, evolution of malaria vaccine is a complex scenario due to the difficulties in developing a suitable vaccine. Extensive studies on development of malaria vaccines have been continuously carried out with enormous funding received by various organizations such as Gates Foundation, National Institute of Health (NIH), pharmaceutical industries such as GSK, European Commission and others.

Almost 50% of the world’s population are at higher risk of acquiring malaria. As per the World Health Organization (WHO), 212 malaria cases were reported in the year 2015 globally with 429,000 deaths due to malaria. Rise in awareness and prevention measures for malaria has led to reduction in cases since 2010. Sub-Saharan Africa consists of the highest rates of incidence for malaria accounting to 90% of global incidence and 92% of malaria deaths. Africa has thus been made the target region for all malarial vaccines development.

The first malaria vaccine by Glaxo SmithKline plc. (GSK) - Mosquirix (RTS,S) received positive scientific opinion from the European Medicines Agency (EMA). Mosquirix is being developed in partnership between GSK and PATH Malaria Vaccine Initiative. Once developed, it would be the first approved vaccine for a parasitic disease and would help curb the incidence of malaria. Ghana, Kenya and Malawi have decided to partner with the WHO in the Malaria Vaccine Implementation Programme (MVIP), which would make Mosquirix available in the aforementioned countries. A pilot study for Mosquirix is said to begin in African regions by January 2018. GSK has assured to not gain any profits from the product. GSK has planned to price the product at cost of manufacture with additional 5% margin. The additional margin shall be invested in further research on malaria.

Market outlook and Key Players

There are many malaria vaccines which are in the pipeline and could be potential candidates in the near future. For example Sanaria Inc.’s vaccine PfSPZ is in Phase I studies and has received fast track designation by the FDA proving it to be a favourable vaccine. This molecule could be a threat to GSK’s Mosquirix. Higher prevalence of malaria and the constant development of successful vaccines catapults the demand for more products thus would lead to a positive growth in the forecast period.

Other key players in the malaria vaccine market that could hold a dominating position are Nobelpharma Co., Ltd., GenVec, Inc.  and Sumaya Biotech.

Pipeline vaccines are as follows:

• Pfs25-EPA/AS01 – Pre clinical
• Pfs230-EPA/AS01- Pre clinical
• CSP mAb- Pre clinical

This report offers:

• An overview of the global malaria vaccine market
• Market evaluation pertaining to each segment
• Qualitative information with respect to market drivers, opportunities and restraints
• A detailed information on the existing malaria vaccine and pipeline vaccines
• A complete understanding on the competitive landscape of the malaria vaccine market. Profiles of key players in terms of financial performance, product portfolio, market trends and general information.

Historical & Forecast Period

This study report represents analysis of each segment from 2023 to 2033 considering 2024 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2025 to 2033.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Malaria Vaccines market are as follows:

• Research and development budgets of manufacturers and government spending
• Revenues of key companies in the market segment
• Number of end users and consumption volume, price and value.
• Geographical revenues generate by countries considered in the report
• Micro and macro environment factors that are currently influencing the Malaria Vaccines market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Key questions answered in this report

• What are the key micro and macro environmental factors that are impacting the growth of Malaria Vaccines market?
• What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
• Estimated forecast and market projections up to 2033.
• Which segment accounts for the fastest CAGR during the forecast period?
• Which market segment holds a larger market share and why?
• Are low and middle-income economies investing in the Malaria Vaccines market?
• Which is the largest regional market for Malaria Vaccines market?
• What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
• Which are the key trends driving Malaria Vaccines market growth?
• Who are the key competitors and what are their key strategies to enhance their market presence in the Malaria Vaccines market worldwide?